Pfizer (WBO:PFE) Additional Paid-In Capital : €84,943 Mil(As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Pfizer Additional Paid-In Capital?

Pfizer's quarterly additional paid-in capital increased from Jun. 2023 (€85,220 Mil) to Sep. 2023 (€86,669 Mil) but then stayed the same from Sep. 2023 (€86,669 Mil) to Dec. 2023 (€84,943 Mil).

Pfizer's annual additional paid-in capital increased from Dec. 2021 (€80,173 Mil) to Dec. 2022 (€86,661 Mil) but then declined from Dec. 2022 (€86,661 Mil) to Dec. 2023 (€84,943 Mil).

Pfizer Additional Paid-In Capital Historical Data

The historical data trend for Pfizer's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pfizer Additional Paid-In Capital Chart

Pfizer Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

78,685.20

72,890.03

80,173.04

86,661.09

84,942.63

Pfizer Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial															86,661.09	86,070.90	85,219.67	86,668.75	84,942.63

Pfizer Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Pfizer Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Pfizer's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Pfizer (WBO:PFE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pfizer Inc (WBO:PFE) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

PFE:USA PFE:Peru PFE:Mexico PFE_KZ:Kazakhstan 1PFE:Italy PFEd:UK 0Q1N:UK PFE:Germany PFE:Chile PFE:Canada PFIZ34:Brazil PFE:Argentina

Address

66 Hudson Boulevard East, New York, NY, USA, 10001-2192

Website

https://www.pfizer.com

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.